• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » COVID-19 vaccine rally sees testing companies’ stocks dip

COVID-19 vaccine rally sees testing companies’ stocks dip

November 10, 2020 By Sean Whooley

(Image courtesy of Abbott)

News of Pfizer and BioNTech’s COVID-19 vaccine candidate performing well has caused markets to rally this week.

The two companies are collaborating on a vaccine candidate that has proven in early clinical data to be approximately 90% effective, and the news helped to propel MassDevice’s MedTech 100 Index to a new record high yesterday.

However, a handful of companies that received boosts earlier during the COVID-19 pandemic because of their production of testing for the virus saw the news of the vaccine sink their stocks a bit, according to historical data from Yahoo Finance.

Thermo Fisher Scientific (NYSE:TMO), which just last month had confirmed an all-time high in per-share price after 48% growth from the beginning of the year thanks in large part to its work during the pandemic, saw a stark drop-off.

The diagnostics company finished last week trading at $527.66 per share, but on Monday it fell to $484.99. Then, today, it got hit harder, falling to $464.76 and marking an 11.9% total descent.

Marlborough, Mass.-based Hologic (NSDQ:HOLX), one of the leaders in testing since the pandemic began and a recipient of multiple government contracts, dipped from $75.05 per share at the end of last week to $68.35 per share yesterday and has since taken an even bigger hit, currently sitting at $65.78 — a 12.4% total drop from last Friday.

Quidel Corp. (NSDW:QDEL) took the largest hit, experiencing a -30.4% drop from the end of last week to today, falling nearly $90 per share from $283.45 to $197.43.

Even Abbott (NYSE:ABT), which benefits from numerous segments helping its stock out without relying on diagnostics, experienced a drop over the past few days, falling from $114.42 to $110.46 for a -3.5% dip. Conversely, Becton Dickinson, which also has other business segments to fall back on, has risen 1.8% since Nov. 6, perhaps slightly bucking the trend of diagnostics developers falling behind as coronavirus vaccine news affects the markets.

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics, Pharmaceutical, Wall Street Beat Tagged With: Abbott, becton dickinson, BioNTech, coronavirus, COVID-19, Hologic, Pfizer, Quidel Corp., Thermo Fisher Scientific

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy